当前期刊: Multiple Sclerosis Journal Go to current issue    加入关注    本刊投稿指南
显示样式:        排序: IF: - GO 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability
    Mult. Scler. J. (IF 5.412) Pub Date : 2021-01-12
    Rocco Capuano; Irati Zubizarreta; Salut Alba-Arbalat; María Sepulveda; Nuria Sola-Valls; Irene Pulido-Valdeolivas; Magi Andorra; Eloy Martinez-Heras; Elisabeth Solana; Elisabet Lopez-Soley; Carmen Montejo; Yolanda Blanco; Jose Ignacio Fernández-Velasco; Antonio Gallo; Alvino Bisecco; Pablo Villoslada; Albert Saiz; Sara Llufriu; Luisa M Villar; Elena H Martinez-Lapiscina

    Background: Prognostic markers are needed to guide multiple sclerosis (MS) management in the context of large availability of disease-modifying drugs (DMDs). Objective: To investigate the role of cerebrospinal fluid (CSF) markers to inform long-term MS outcomes. Methods: Demographic features, IgM index, oligoclonal IgM bands (OCMB), lipid-specific OCMB, CSF neurofilament light chain protein levels

    更新日期:2021-01-12
  • Determinants of therapeutic lag in multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2021-01-11
    Izanne Roos; Emmanuelle Leray; Federico Frascoli; Romain Casey; J William L Brown; Dana Horakova; Eva Kubala Havrdova; Marc Debouverie; Maria Trojano; Francesco Patti; Guillermo Izquierdo; Sara Eichau; Gilles Edan; Alexandre Prat; Marc Girard; Pierre Duquette; Marco Onofrj; Alessandra Lugaresi; Pierre Grammond; Jonathan Ciron; Aurélie Ruet; Serkan Ozakbas; Jérôme De Seze; Céline Louapre; Hélène Zephir;

    Background: A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups. Objectives: The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation. Methods: Data from MSBase, a multinational multiple sclerosis (MS) registry, and

    更新日期:2021-01-11
  • Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort
    Mult. Scler. J. (IF 5.412) Pub Date : 2021-01-08
    Kathryn C Fitzgerald; Anne Damian; Devon Conway; Ellen M Mowry

    Objective: The objective of this study is to assess the association between vascular comorbidity burden with clinical and imaging features of disease burden in a large population of people with multiple sclerosis (MS). Methods: We included participants from the MS Partners Advancing Technology Health Solutions (MS PATHS) cohort. We evaluated if vascular comorbidities (diabetes, hypertension, and dyslipidemia)

    更新日期:2021-01-08
  • 7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres – No
    Mult. Scler. J. (IF 5.412) Pub Date : 2021-01-06
    Gabriel Gonzalez-Escamilla; Sergiu Groppa

    Magnetic resonance imaging (MRI) has gained an essential role in state-of-the-art research and clinical practice for neuroimmunological conditions and especially multiple sclerosis (MS) by providing important information on focal inflammation with demyelination and structural alterations with atrophy and neurodegeneration.

    更新日期:2021-01-06
  • 7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres – Yes
    Mult. Scler. J. (IF 5.412) Pub Date : 2021-01-06
    Céline Louapre; Ysoline Beigneux

    Over the past 10 years, 7 Tesla (7 T) magnetic resonance imaging (MRI) has brought many advances in the in vivo exploration of the pathophysiological mechanisms of multiple sclerosis (MS). Thanks to increased signal-to-noise ratio and contrast-to-noise ratio, as well as increased spatial resolution (voxel size below 500 µm3), 7 T MRI provides access to precise anatomical details, not or barely visible

    更新日期:2021-01-06
  • Cumulative effects of therapies on disability in relapsing multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2021-01-06
    Fabien Rollot; Romain Casey; Emmanuelle Leray; Marc Debouverie; Gilles Edan; Sandrine Wiertlewski; Sandra Vukusic; David-Axel Laplaud

    Background: Long-term effectiveness of treatment remains a key question in multiple sclerosis (MS) and the cumulative effects of past treatment have not been investigated so far. Objective: Explore the relationship between treatment exposure and disability risk in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: A total of 2285 adult patients from the French nationwide cohort were

    更新日期:2021-01-06
  • Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder
    Mult. Scler. J. (IF 5.412) Pub Date : 2021-01-06
    Gabrielle Macaron; Jean Khoury; James Bena; Meagan Seay; Robert A Bermel; Jeffrey A Cohen; Mary R Rensel

    Background: Severe residual visual loss (SRVL) is frequent in neuromyelitis optica spectrum disorders (NMOSD). Identifying higher-risk patients at onset is important to prevent disability accumulation. Objective: To determine predictors of SRVL in a large NMOSD cohort. Methods: Patient characteristics at last visual acuity (VA) evaluation were retrospectively collected. VA was scored 0: better than

    更新日期:2021-01-06
  • 7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centers – Commentary
    Mult. Scler. J. (IF 5.412) Pub Date : 2021-01-06
    Pascal Sati; Daniel S Reich

    Seven-tesla (7T) magnetic resonance imaging (MRI) has become an important tool to investigate noninvasively the cerebral pathology affecting patients with multiple sclerosis (MS). Indeed, the superior image resolution and contrast achieved at 7T has allowed researchers to study brain lesions in great detail and advance our understanding of the formation and extent of these lesions throughout the evolution

    更新日期:2021-01-06
  • An enrichment strategy for clinical trials in SPMS
    Mult. Scler. J. (IF 5.412) Pub Date : 2021-01-06
    Marcus W Koch; Luanne Metz; Gary Cutter

    Background: We recently compared clinical outcomes in secondary progressive MS (SPMS) clinical trials and found an association of timed 25 foot walk (T25FW) worsening events and baseline disability scores. It is unclear whether disability worsening in clinical trials is comparable to that seen in clinical practice. Objective: The objective of this study is to compare disability worsening between the

    更新日期:2021-01-06
  • Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2021-01-05
    Ruth Ann Marrie; Stella Leung; Gary R Cutter; Robert J Fox; Amber Salter

    Background: Outcome measures need to be valid and have good test–retest reliability and responsiveness. We compared the responsiveness of the RAND-12 and the Health Utilities Index—mark III (HUI3) in persons with multiple sclerosis (MS). Methods: In Spring 2018 and 2019, North American Research Committee on Multiple Sclerosis (NARCOMS) registry participants completed the HUI3, the RAND-12, and reported

    更新日期:2021-01-05
  • Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-17
    Nete Munk Nielsen; Sanne Gørtz; Henrik Hjalgrim; Klaus Rostgaard; Kassandra L Munger; Alberto Ascherio; Melinda Magyari; Egon Stenager; Morten Frisch

    Background: Previous studies suggest a 3- to-10-fold increased risk of multiple sclerosis (MS) in offspring of mothers with diabetes mellitus (DM). Objectives: To examine MS risk in offspring of diabetic mothers, overall and according to type of maternal DM, that is, pregestational DM or gestational DM, as well as to examine MS risk among offspring of diabetic fathers. Methods: The study cohort included

    更新日期:2020-12-17
  • Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-17
    Manuel Comabella; Claudia Deutschmann; Luciana Midaglia; Peter Schierack; Júlia Martínez; Dirk Roggenbuck; Xavier Montalban

    Autoimmunity to chitinase 3-like 1 (CHI3L1) has recently been reported in hepatic and bowel inflammatory conditions. Considering that CHI3L1 plays a role as prognostic biomarker in multiple sclerosis (MS), here we investigated CHI3L1 as potential autoantigenic target in the disease. We determined serum CHI3L1 autoantibodies by enzyme-linked immunosorbent assay (ELISA) in a cohort of 60 untreated MS

    更新日期:2020-12-17
  • Erratum
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-16

    Van Geel F, Veldkamp R, Severijns D, Dalgas U, & Feys P. Day-to-day reliability, agreement and discriminative validity of measuring walking-related performance fatigability in persons with multiple sclerosis. Multiple Sclerosis Journal 2020; 26(13): 1785-1789. doi:10.1177/1352458519872465

    更新日期:2020-12-16
  • Serum ceramide levels are altered in multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-14
    Angeliki G Filippatou; Mohammed Moniruzzaman; Elias S Sotirchos; Kathryn C Fitzgerald; Grigorios Kalaitzidis; Jeffrey Lambe; Eleni Vasileiou; Shiv Saidha; Jerry L Prince; Norman Haughey; Peter A Calabresi; Pavan Bhargava

    Background: Sphingolipids are myelin components and inflammatory signaling intermediates. Sphingolipid metabolism may be altered in people with multiple sclerosis (PwMS), but existing studies are limited by small sample sizes. Objectives: To compare the levels of serum ceramides between PwMS and healthy controls (HCs) and to determine whether ceramide levels correlate with disability status, as well

    更新日期:2020-12-14
  • Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-14
    Peter A Calabresi; Douglas L Arnold; Dipen Sangurdekar; Carol M Singh; Arman Altincatal; Carl de Moor; Bob Engle; Jaya Goyal; Aaron Deykin; Suzanne Szak; Bernd C Kieseier; Richard A Rudick; Tatiana Plavina

    Objective: To understand how longitudinal serum neurofilament light chain (sNfL) patterns can inform its use as a prognostic biomarker in multiple sclerosis (MS) and evaluate whether sNfL reflects MS disease activity and disease-modifying therapy usage. Methods: This was a post hoc analysis of longitudinal data and samples from the ADVANCE trial (NCT00906399) of patients with relapsing–remitting MS

    更新日期:2020-12-14
  • Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-14
    Angeliki G Filippatou; Eleni S Vasileiou; Yufan He; Kathryn C Fitzgerald; Grigorios Kalaitzidis; Jeffrey Lambe; Maureen A Mealy; Michael Levy; Yihao Liu; Jerry L Prince; Ellen M Mowry; Shiv Saidha; Peter A Calabresi; Elias S Sotirchos

    Background: Prior studies have suggested that subclinical retinal abnormalities may be present in aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), in the absence of a clinical history of optic neuritis (ON). Objective: Our aim was to compare retinal layer thicknesses at the fovea and surrounding macula between AQP4-IgG+ NMOSD eyes without a history

    更新日期:2020-12-14
  • Depression in multiple sclerosis across the adult lifespan
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-14
    Carol K Chan; Fan Tian; Daniela Pimentel Maldonado; Ellen M Mowry; Kathryn C Fitzgerald

    Objectives: The objective of this study is to examine the burden of depressive symptoms across the adult age span in people with multiple sclerosis (MS) and test if the relationship between depressive symptoms and MS characteristics vary across age groups. Methods: In analyses of the MS Partners Advancing Technology and Health Solutions (MS PATHS) network of adults with MS, we compared the prevalence

    更新日期:2020-12-14
  • Identification of regulatory T cell molecules associated with severity of multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-10
    MA Tapia-Maltos; I Treviño-Frenk; HB García-González; M Rosetti; V Barriga-Maldonado; F Morales-Ramírez; DC López-Hernández; F Rosetti; JC Crispín

    Background: Regulatory CD4+ T cells (Tregs) exhibit functional alterations in patients with multiple sclerosis (MS). Transforming growth factor (TGF)-β is a key regulator of Treg development and function. Objective: The objective of this study is to determine whether the expression of functionally relevant TGF-β-regulated molecules is altered in Tregs from patients with MS. Methods: Expression of nine

    更新日期:2020-12-10
  • Expanding spectrum of opportunistic infections associated with dimethyl fumarate
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-10
    Tiffany Kim; David Croteau; Allen Brinker; David E Jones; Paul R Lee; Cindy M Kortepeter

    Background: Only progressive multifocal leukoencephalopathy (PML) is currently described in the dimethyl fumarate (DMF) prescribing information. Objectives: To describe opportunistic infections (OIs), other than PML, reported in association with DMF. Methods: The FDA Adverse Event Reporting System (FAERS) and medical literature were searched. Results: We retrieved 34 cases of serious OIs with a causal

    更新日期:2020-12-10
  • Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-09
    Ilse M Nauta; Shanna D Kulik; Lucas C Breedt; Anand JC Eijlers; Eva MM Strijbis; Dirk Bertens; Prejaas Tewarie; Arjan Hillebrand; Cornelis J Stam; Bernard MJ Uitdehaag; Jeroen JG Geurts; Linda Douw; Brigit A de Jong; Menno M Schoonheim

    Background: Cognitive decline remains difficult to predict as structural brain damage cannot fully explain the extensive heterogeneity found between MS patients. Objective: To investigate whether functional brain network organization measured with magnetoencephalography (MEG) predicts cognitive decline in MS patients after 5 years and to explore its value beyond structural pathology. Methods: Resting-state

    更新日期:2020-12-09
  • Clinical significance of a single cerebrospinal fluid immunoglobulin band: A retrospective study
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-09
    Maud Tusseau; Estelle Cheli; Romain Marignier; Françoise Poitevin; Christophe Malcus; Morgane Gossez; Julien Bancel; Guillaume Monneret; Sandra Vukusic

    Background: To demonstrate an inflammatory process in the central nervous system, the presence of at least two immunoglobulin (Ig) bands in the cerebrospinal fluid (CSF) is required. So far, the presence of a single abnormal Ig band is considered as negative. Objective: The objective was to assess retrospectively the significance of a single CSF Ig band in clinical practice. Methods and results: Out

    更新日期:2020-12-09
  • Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-07
    Ismail Koubiyr; Mathilde Deloire; Bruno Brochet; Pierre Besson; Julie Charré-Morin; Aurore Saubusse; Thomas Tourdias; Aurélie Ruet

    Background: The relationship between structural and functional deficits in multiple sclerosis (MS) is unclear. Objective: This study explored structure-function relationships during the 5 years following a clinically isolated syndrome and their role in cognitive performance. Methods: Thirty-two patients were enrolled after their first neurological episode suggestive of MS and followed for 5 years,

    更新日期:2020-12-07
  • MSVirtual 2020 – Platform Presentations
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-07

    S. Pittock1, K. Fujihara2, J. Palace3, A. Berthele4, H.J. Kim5, C. Oreja-Guevara6, I. Nakashima7, M. Levy8, A. Pace9, M. Yountz9, L. Miller9, R. Armstrong10, D. WingerchUK11

    更新日期:2020-12-07
  • MSVirtual 2020 – Poster Abstracts
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-07

    C. Maguire, B. Caslin, S. Bazzi, E. Melamed, D. Wylie

    更新日期:2020-12-07
  • MSVirtual 2020 – Late Breaking News
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-07

    M. Lohrberg1, A. Winkler1, J. Franz1, F. Van Der Meer1, A. Barrantes-Freer2, C. Stadelmann1

    更新日期:2020-12-07
  • MSVirtual 2020 – Author Index
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-07

    Aaen G..........................P1082, PS04.04

    更新日期:2020-12-07
  • Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-03
    Sandra Vukusic; Iuliana Ionescu; Catherine Cornu; Nadine Bossard; Françoise Durand-Dubief; François Cotton; Luca Durelli; Romain Marignier; Laurence Gignoux; David-Axel Laplaud; Thibault Moreau; Pierre Clavelou; Jérôme De Seze; Marc Debouverie; David Brassat; Jean Pelletier; Christine Lebrun-Frenay; Emmanuelle Le Page; Giovanni Castelnovo; Eric Berger; Patrick Hautecoeur; Olivier Heinzlef; Maria Trojano;

    Background: Sex steroids could explain the course of multiple sclerosis (MS) in pregnancy. Objective: To compare the annualized relapse rate (ARR) 12 weeks post-partum in women treated with nomegestrol acetate (NOMAc) and 17-beta-estradiol (E2) versus placebo. Methods: POPARTMUS is a randomized, proof-of-concept trial in women with MS, receiving oral NOMAc 10 mg/day and transdermal estradiol 75 µg/week

    更新日期:2020-12-03
  • Table of Contents
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-02

    Please be aware that it was the submitter’s responsibility to fill in all data correctly and completely. Any errors in spelling, grammar or scientific fact have been reproduced as typed by the author/submitter.

    更新日期:2020-12-03
  • Table of Contents by Submission Group
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-02

    Please be aware that it was the submitter’s responsibility to fill in all data correctly and completely. Any errors in spelling, grammar or scientific fact have been reproduced as typed by the author/submitter.

    更新日期:2020-12-03
  • RIMS Digital Conference
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-02

    Samantha Turner1, Jenny Freeman2

    更新日期:2020-12-03
  • Accurate classification of secondary progression in multiple sclerosis using a decision tree
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-02
    Ryan Ramanujam; Feng Zhu; Katharina Fink; Virginija Danylaitė Karrenbauer; Johannes Lorscheider; Pascal Benkert; Elaine Kingwell; Helen Tremlett; Jan Hillert; Ali Manouchehrinia; The BeAMS Study group

    Background: The absence of reliable imaging or biological markers of phenotype transition in multiple sclerosis (MS) makes assignment of current phenotype status difficult. Objective: The authors sought to determine whether clinical information can be used to accurately assign current disease phenotypes. Methods: Data from the clinical visits of 14,387 MS patients in Sweden were collected. Classifying

    更新日期:2020-12-02
  • Towards an objective classification of multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-02
    Arman Eshaghi

    A more objective classification of multiple sclerosis (MS) has long been the aim of our field, or such, wrote Charles Poser1 in March 1965: ‘[an aim of this study] was to establish a more objective system of scoring [and classification], based upon clinical signs and symptoms’. This ambition, however, has remained elusive half a century later.

    更新日期:2020-12-02
  • Multifocal visual evoked potential evaluation for diagnosis of acute optic neuritis and for prediction of visual outcome and ganglion cell layer thinning following optic neuritis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-02
    Gorm Pihl-Jensen; Benedikte Wanscher; Jette Lautrup Frederiksen

    Background:: While damage to the optic nerve following optic neuritis (ON) is readily quantifiable, the evaluation of prognosis for visual function and neuroaxonal loss in the acute ON is challenging. Objective:: The objective of this study is to investigate the value of multifocal visual evoked potential (mfVEP) in acute ON, diagnostically for acute ON and prognostically for visual outcome and subsequent

    更新日期:2020-12-02
  • Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-12-01
    Sarah A Morrow; Devon Conway; Tom Fuchs; Curtis Wojcik; Mahmut Unverdi; Faizan Yasin; Jeta Pol; Sveltlana Eckert; David H Hojnacki; Michael Dwyer; Robert Zivadinov; Bianca Weinstock-Guttman; Ralph HB Benedict

    Background: Cognition is affected by relapses in persons with multiple sclerosis (PwMS), yet the Expanded Disability Status Scale (EDSS) does not readily detect cognitive changes. Objective: The objective of this study is to improve the detection of cognitive decline during relapses, by incorporating the Symbol Digit Modalities Test (SDMT) into the cerebral Functional System Score (CFSS) of the EDSS

    更新日期:2020-12-02
  • Youth with multiple sclerosis have low levels of fitness
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-27
    Samantha Stephens; Tara Berenbaum; Marcia Finlayson; Robert W Motl; E Ann Yeh

    Background: Moderate and vigorous physical activity is associated with improved outcomes in youth with multiple sclerosis (MS). Physical fitness may also influence disease and health outcomes in this population. Objectives: To determine if there were differences in physical fitness between youth with MS and healthy controls (HC). To examine relationships between physical fitness, physical activity

    更新日期:2020-11-27
  • An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-25
    Andrew R Romeo; William M Rowles; Erica S Schleimer; Patrick Barba; Wan-Yu Hsu; Refujia Gomez; Adam Santaniello; Chao Zhao; Jennifer R Pearce; JB Jones; Bruce C Cree; Stephen L Hauser; Jeffrey M Gelfand; Walter F Stewart; Douglas S Goodin; Riley M Bove

    Background: In persons with multiple sclerosis (MS), the Expanded Disability Status Scale (EDSS) is the criterion standard for assessing disability, but its in-person nature constrains patient participation in research and clinical assessments. Objective: The aim of this study was to develop and validate a scalable, electronic, unsupervised patient-reported EDSS (ePR-EDSS) that would capture MS-related

    更新日期:2020-11-26
  • Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-24
    Martin Langeskov-Christensen; Lars Grøndahl Hvid; Henrik Boye Jensen; Helle Hvilsted Nielsen; Thor Petersen; Egon Stenager; Päivi Hämäläinen; Ulrik Dalgas

    Background Cognitive impairment is highly prevalent in multiple sclerosis (MS). Progressive aerobic exercise (PAE) represents a promising approach toward preservation or even improvement of cognitive performance in people with MS (pwMS). Objective To investigate the effects of PAE on the cognitive domains of information processing, learning and memory, and verbal fluency in pwMS. Methods This randomized

    更新日期:2020-11-25
  • Expansion of chronic lesions is linked to disease progression in relapsing–remitting multiple sclerosis patients
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-20
    Samuel Klistorner; Michael H Barnett; Con Yiannikas; Joshua Barton; John Parratt; Yuyi You; Stuart L Graham; Alexander Klistorner

    Background: Slow-burning inflammation is putatively associated with lesion expansion and leads to progressive loss of axons and disability worsening. Objective: To investigate the incidence and extent of chronic white matter lesion expansion in relapsing–remitting multiple sclerosis (RRMS) patients and to evaluate its relationship with biomarkers of disease progression. Methods: Pre- and post-gadolinium

    更新日期:2020-11-21
  • Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-19
    Pietro Iaffaldano; Giuseppe Lucisano; Francesco Patti; Vincenzo Brescia Morra; Giovanna De Luca; Alessandra Lugaresi; Mauro Zaffaroni; Matilde Inglese; Giuseppe Salemi; Eleonora Cocco; Antonella Conte; Diana Ferraro; Simonetta Galgani; Roberto Bergamaschi; Carlo Pozzilli; Marco Salvetti; Giacomo Lus; Marco Rovaris; Giorgia Teresa Maniscalco; Francesco Ottavio Logullo; Damiano Paolicelli; Mariaclara

    Background: No uniform criteria for a sensitive identification of the transition from relapsing–remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available. Objective: To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA). Methods: Relapsing-onset MS patients (n = 19,318)

    更新日期:2020-11-19
  • COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-18
    Alice Laroni; Irene Schiavetti; Maria Pia Sormani; Antonio Uccelli

    The CoronaVirus Disease 19 (COVID-19) pandemic is a threat of particular concern for people affected by chronic immune-mediated diseases, such as multiple sclerosis (MS), who are often treated with immunomodulatory and immunosuppressive drugs, which may increase the risk of infections in general. At the beginning of the COVID-19 pandemic, empirical guidelines on how to manage treatments for immune-mediated

    更新日期:2020-11-18
  • Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-18
    Bruce AC Cree; Baldur Magnusson; Nicolas Rouyrre; Robert J Fox; Gavin Giovannoni; Patrick Vermersch; Amit Bar-Or; Ralf Gold; Daniela Piani Meier; Göril Karlsson; Davorka Tomic; Christian Wolf; Frank Dahlke; Ludwig Kappos

    Background: In multiple sclerosis, impact of treatment on disability progression can be confounded if treatment also reduces relapses. Objective: To distinguish siponimod’s direct effects on disability progression from those on relapses in the EXPAND phase 3 trial. Methods: Three estimands, one based on principal stratum and two on hypothetical scenarios (no relapses, or equal relapses in both treatment

    更新日期:2020-11-18
  • Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-16
    Lisa Glukhovsky; Daniel Kurz; Rachel Brandstadter; Victoria M Leavitt; Stephen Krieger; Michelle Fabian; Ilana Katz Sand; Sylvia Klineova; Claire S Riley; Fred D Lublin; Aaron E Miller; James F Sumowski

    Background: Persons with multiple sclerosis (MS) and depression symptoms report real-world cognitive difficulties that may be missed by laboratory cognitive tests. Objective: To examine the relationship of depressive symptoms to cognitive monotasking versus multitasking in early MS. Method: Persons with early MS (n = 185; ⩽5 years diagnosed) reported mood, completed monotasking and multitasking cognitive

    更新日期:2020-11-16
  • Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-13
    Paolo Preziosa; Elisabetta Pagani; Lucia Moiola; Mariaemma Rodegher; Massimo Filippi; Maria A Rocca

    Background: In multiple sclerosis (MS), up to 57% of white matter lesions are chronically active. These slowly expanding lesions (SELs) contribute to disability progression. Objective: The aim of this study is to compare fingolimod and natalizumab effects on progressive linearly enlarging lesions (i.e. SELs), a putative biomarker of smouldering inflammation. Methods: Relapsing-remitting MS patients

    更新日期:2020-11-13
  • The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case–control study
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-12
    Mirla Avila; Annette Okai; Smathorn Thakolwiboon; Collin O’Bryan; Murali Mohan Reddy Gopireddy; Sasikanth Gorantla

    Tonsils are believed to be the initial site of the John Cunningham virus (JCV) infection. The long-term effect of childhood tonsillectomy on JCV status in multiple sclerosis (MS) patients has not been investigated. In this retrospective case–control study, we analyzed data of 144 JCV seropositive cases and 82 JCV seronegative controls from three outpatient MS clinics in the United States. Early tonsillectomy

    更新日期:2020-11-13
  • Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-12
    Rosaria Sacco; Andrea Braga; Giulio Disanto; Giuseppe Alessandro Digesu; Paolo Maino; Eva Koetsier; Giorgio Caccia; Maurizio Serati; Julien Renard; Claudio Gobbi; Chiara Zecca

    Background: Neurogenic bowel dysfunctions (NBDs) in the form of both fecal incontinence (FI) and functional constipation (FC) are frequent in multiple sclerosis (MS) patients and significantly affect their quality of life. Therapeutic options are limited. Objective: To investigate effectiveness of percutaneous posterior tibial nerve stimulation (PTNS) in MS patients suffering from FI and FC. Methods:

    更新日期:2020-11-13
  • Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-12
    Henrik Heitmann; Till F M Andlauer; Thomas Korn; Mark Mühlau; Peter Henningsen; Bernhard Hemmer; Markus Ploner

    Fatigue, depression, and pain affect the majority of multiple sclerosis (MS) patients, which causes a substantial burden to patients and society. The pathophysiology of these symptoms is not entirely clear, and current treatments are only partially effective. Clinically, these symptoms share signs of anhedonia, such as reduced motivation and a lack of positive affect. In the brain, they are associated

    更新日期:2020-11-13
  • The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-12
    Mohammad Ehsanul Karim; Fabio Pellegrini; Robert W Platt; Gabrielle Simoneau; Julie Rouette; Carl de Moor

    Background: Propensity score (PS) analyses are increasingly used in multiple sclerosis (MS) research, largely owing to the greater availability of large observational cohorts and registry databases. Objective: To evaluate the use and quality of reporting of PS methods in the recent MS literature. Methods: We searched the PubMed database for articles published between January 2013 and July 2019. We

    更新日期:2020-11-13
  • Atlas of MS 2020: Informing global policy change
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-11
    Timothy Coetzee; Alan J Thompson

    As the second decade of the 21st century draws to a close, we can take stock and potentially congratulate ourselves on the remarkable progress in the treatment and care of multiple sclerosis (MS). Improvements in the diagnosis of MS, proliferation of treatment options for relapsing forms of MS, and some, albeit modestly useful, treatments for the progressive forms of the disease, alongside a robust

    更新日期:2020-11-12
  • Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-11
    Clare Walton; Rachel King; Lindsay Rechtman; Wendy Kaye; Emmanuelle Leray; Ruth Ann Marrie; Neil Robertson; Nicholas La Rocca; Bernard Uitdehaag; Ingrid van der Mei; Mitchell Wallin; Anne Helme; Ceri Angood Napier; Nick Rijke; Peer Baneke

    Background: High-quality epidemiologic data worldwide are needed to improve our understanding of disease risk, support health policy to meet the diverse needs of people with multiple sclerosis (MS) and support advocacy efforts. Objectives: The Atlas of MS is an open-source global compendium of data regarding the epidemiology of MS and the availability of resources for people with MS reported at country

    更新日期:2020-11-12
  • Cotinine as a measure of smoking in observational studies of multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-10
    Anna Karin Hedström; T Olsson; L Alfredsson

    Studies using cotinine levels to define smokers have generally failed to detect an association between smoking and multiple sclerosis (MS). Using a Swedish population-based case-control study, we show that associations in relation to MS risk and progression differ considerably depending on how smoking is measured. The risk of conversion into secondary progressive disease was increased among smokers

    更新日期:2020-11-12
  • Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-05
    KH Lam; KA Meijer; FC Loonstra; EME Coerver; J Twose; E Redeman; B Moraal; F Barkhof; V de Groot; BMJ Uitdehaag; J Killestein

    Background: Clinical measures in multiple sclerosis (MS) face limitations that may be overcome by utilising smartphone keyboard interactions acquired continuously and remotely during regular typing. Objective: The aim of this study was to determine the reliability and validity of keystroke dynamics to assess clinical aspects of MS. Methods: In total, 102 MS patients and 24 controls were included in

    更新日期:2020-11-06
  • High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-05
    Tilman Schneider-Hohendorf; Andreas Schulte-Mecklenbeck; Patrick Ostkamp; Claudia Janoschka; Marc Pawlitzki; Felix Luessi; Frauke Zipp; Sven G Meuth; Luisa Klotz; Heinz Wiendl; Catharina C Gross; Nicholas Schwab

    Background: Progressive multifocal leukoencephalopathy (PML) can in rare cases occur in natalizumab-treated patients with high serum anti-JCPyV antibodies, hypothetically due to excessive blockade of immune cell migration. Objective: Immune cell recruitment to the central nervous system (CNS) was assessed in relapsing-remitting multiple sclerosis (RRMS) patients stratified by low versus high anti-JCPyV

    更新日期:2020-11-06
  • Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-04
    Korhan Buyukturkoglu; Dana Zeng; Srinidhi Bharadwaj; Ceren Tozlu; Enricomaria Mormina; Kay C Igwe; Seonjoo Lee; Christian Habeck; Adam M Brickman; Claire S Riley; Philip L De Jager; James F Sumowski; Victoria M Leavitt

    Objective: To build a model to predict cognitive status reflecting structural, functional, and white matter integrity changes in early multiple sclerosis (MS). Methods: Based on Symbol Digit Modalities Test (SDMT) performance, 183 early MS patients were assigned “lower” or “higher” performance groups. Three-dimensional (3D)-T2, T1, diffusion weighted, and resting-state magnetic resonance imaging (MRI)

    更新日期:2020-11-04
  • Understanding the pathophysiology of cognitive changes in MS: A step forward
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-11-04
    Maria Pia Amato; Emilio Portaccio; Ermelinda De Meo

    The literature on cognition in people with multiple sclerosis (MS) has grown exponentially over the last 25 years, and cognitive dysfunction is now recognized as a core symptom of the disease. Impairment of cognitive function is estimated to affect 34%–65% of adult patients1 and nearly 30% of patients under 18 years of age.2 MS-related cognitive impairment presents a considerable burden to patients

    更新日期:2020-11-04
  • Exercise and the brain in multiple sclerosis
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-10-30
    Brian M Lozinski; V Wee Yong

    While people with multiple sclerosis (PwMS) historically were advised to avoid physical activity to reduce symptoms such as fatigue, they are now encouraged to remain active and to enlist in programs of exercise. However, despite an extensive current literature that exercise not only increases physical well-being but also their cognition and mental health, many PwMS are not meeting recommended levels

    更新日期:2020-10-30
  • BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-10-30
    Mikael Cohen; Lydiane Mondot; Florence Bucciarelli; Béatrice Pignolet; David-Axel Laplaud; Sandrine Wiertlewski; Bruno Brochet; Aurélie Ruet; Gilles Defer; Nathalie Derache; Patrick Vermersch; Hélène Zephir; Marc Debouverie; Guillaume Mathey; Eric Berger; Chrystelle Cappé; Pierre Labauge; Clarisse Carra; Jérôme De Seze; Kevin Bigaut; David Brassat; Christine Lebrun-Frenay

    Background: There are few head-to-head studies to compare highly active treatments in multiple sclerosis (MS) Objective: The aim of this study was to compare the effectiveness between natalizumab (NTZ) and fingolimod (FTY) in active relapsing–remitting MS Method: Best Escalation STrategy in Multiple Sclerosis (BEST-MS) is a multicentric, prospective study with a 12-month follow-up including patients

    更新日期:2020-10-30
  • The emerging role of artificial intelligence in multiple sclerosis imaging
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-10-28
    H. M. Rehan Afzal; Suhuai Luo; Saadallah Ramadan; Jeannette Lechner-Scott

    Background: Computer-aided diagnosis can facilitate the early detection and diagnosis of multiple sclerosis (MS) thus enabling earlier interventions and a reduction in long-term MS-related disability. Recent advancements in the field of artificial intelligence (AI) have led to the improvements in the classification, quantification and identification of diagnostic patterns in medical images for a range

    更新日期:2020-10-29
  • Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-10-26
    Ricardo Kosch; Insa Schiffmann; Martin Daumer; Christian Lederer; Antonio Scalfari; Ian Galea; Jutta Scheiderbauer; Anne Rahn; Christoph Heesen

    Background: Prognostic counselling is a sensitive issue in medicine and especially so in MS due to the highly heterogeneous disease course. However, people with MS (pwMS) seek prognostic information. The web-based ‘Evidence-Based Decision Support Tool in Multiple Sclerosis’ (EBDiMS) uses data of 717 patients from the London/Ontario cohort to calculate personalized long-term prognostic information.

    更新日期:2020-10-29
  • Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression
    Mult. Scler. J. (IF 5.412) Pub Date : 2020-10-26
    Luca Prosperini; Shalom Haggiag; Carla Tortorella; Simonetta Galgani; Claudio Gasperini

    Objective: To verify the hypothesis of an age-dependent increase of infections and neoplasms in patients with multiple sclerosis (MS) under disease-modifying treatments (DMTs) with different mechanisms of action. Methods: We extracted relevant data from 45 randomized clinical trials (RCTs) on currently licensed DMTs. We fitted inverse-variance weighted meta-regressions with random-effects models to

    更新日期:2020-10-29